levodopa has been researched along with minocycline in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Dixit, A; Mishra, M; Prakash, O; Singh, MP; Singh, PK; Srivastava, G; Verma, D | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Bird, LM; Tan, WH | 1 |
| Cronin, A; Grealy, M | 1 |
| du Mee, D; Elgersma, Y; Kingma, J; Santos, SS; Sonzogni, M; van Woerden, GM; Wallaard, I | 1 |
| Danilchenko, V; Dhar, A; Matiashova, L; Miranda, AV; Papakosta, V; Tsagkaris, C; Zacharopoulou, L | 1 |
| Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B | 1 |
2 review(s) available for levodopa and minocycline
| Article | Year |
|---|---|
Pharmacological therapies for Angelman syndrome.
Topics: Angelman Syndrome; Animals; Clinical Trials as Topic; Disease Models, Animal; Gene Silencing; Levodopa; Mice; Minocycline; Oligoribonucleotides, Antisense; Seizures; Sleep Wake Disorders; Topoisomerase Inhibitors; Ubiquitin-Protein Ligases | 2017 |
Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Topics: Angelman Syndrome; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Buspirone; Diet, Ketogenic; Dietary Supplements; Disease Models, Animal; Gene Silencing; Genetic Therapy; Humans; Levodopa; Mice; Minocycline; Neurons; Signal Transduction; Topoisomerase I Inhibitors; Ubiquitin-Protein Ligases | 2020 |
9 other study(ies) available for levodopa and minocycline
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Homeodomain Proteins; Levodopa; Male; Maneb; Metalloporphyrins; Mice; Microglia; Minocycline; Mitochondria; Paraquat; Parkinson Disease, Secondary; Proteome; Stathmin; Superoxide Dismutase | 2013 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel
Topics: Angelman Syndrome; Animals; Behavior Rating Scale; Behavior, Animal; Disease Models, Animal; Female; Levodopa; Male; Mice, Mutant Strains; Minocycline; Mutation; Phenotype; Ubiquitin-Protein Ligases | 2018 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; Inflammation; Levodopa; Mice; Microglia; Minocycline; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |